Who Exports Furosemide from India — 333 Suppliers Behind a $70.5M Market
India's furosemide export market is supplied by 333 active exporters who collectively shipped $70.5M across 4,657 shipments. BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED leads with a 25.2% market share, followed by GRAVITI PHARMACEUTICALS PRIVATE LIMITED and IPCA LABORATORIES LIMITED. The top 5 suppliers together control 58.0% of total export value, reflecting a moderately competitive market structure.

Top Furosemide Exporters from India — Ranked by Export Value
BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED is the leading furosemide exporter from India, holding a 25.2% share of the $70.5M market across 4,657 shipments from 333 exporters. The top 5 suppliers — BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED, GRAVITI PHARMACEUTICALS PRIVATE LIMITED, IPCA LABORATORIES LIMITED, PFIZER HEALTHCARE INDIA PRIVATE LIMITED, AVET LIFESCIENCES PRIVATE LIMITED — collectively control 58.0% of total export value, indicating a moderately concentrated market. Individual shares are: BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED (25.2%), GRAVITI PHARMACEUTICALS PRIVATE LIMITED (20.3%), IPCA LABORATORIES LIMITED (4.8%), PFIZER HEALTHCARE INDIA PRIVATE LIMITED (3.9%), AVET LIFESCIENCES PRIVATE LIMITED (3.8%).
Top Furosemide Exporters from India
Ranked by export value · 333 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $17.8M | 12 | 25.2% |
| 2 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $14.3M | 1 | 20.3% |
| 3 | IPCA LABORATORIES LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $3.4M | 6 | 4.8% |
| 4 | PFIZER HEALTHCARE INDIA PRIVATE LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $2.8M | 1 | 3.9% |
| 5 | AVET LIFESCIENCES PRIVATE LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $2.7M | 1 | 3.8% |
| 6 | MYLAN LABORATORIES LIMITED FUROSEMIDE TABLETS 40MG (FUROSEMIDE ARROFUROSEMIDE TABLETS 40MG(FUROSEMIDE ARROWFUROSEMIDE TABLETS 40 MG | $2.3M | 1 | 3.3% |
| 7 | SANDOZ PRIVATE LIMITED FUROSEMIDE TAB 40MG IN91 SH EU 02 MATERIFUROSEMIDE TAB 40MG IN91 SH EU 02 MATERIAL NO - 42024057MATERIAL NO - 42024057 FUROSEMIDE TAB 40MG IN91 SH EU 02 | $2.3M | 2 | 3.3% |
| 8 | EMCURE PHARMACEUTICALS LIMITED FUROSEMIDE INJ.40MG/4MLX25 MAR CA SN (NOHARMLESS MEDICINES MINT-FUROSEMIDE (FUFUROSEMIDE INJECTION USP 4 ML | $2.1M | 1 | 3.0% |
| 9 | GLAND PHARMA LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $1.9M | 5 | 2.8% |
| 10 | LINCOLN PHARMACEUTICALS LTD FUROSEMIDE INJECTION BP 10 MG (FUROSEMIDE TABLETS BP 40 MG (49FUROSEMIDE INJECTION USP 20MG/2ML 10MG/ML GUFRUSEMID | $1.7M | 3 | 2.5% |
| 11 | MAIVA PHARMA PRIVATE LIMITED FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $1.7M | 1 | 2.4% |
| 12 | AUROBINDO PHARMA LTD FUROSEMIDE TABLETS 40MG (FUROSEMIDE ARROFUROSEMIDE TABLETS 40MG(FUROSEMIDE ARROWFUROSEMIDE TABLETS 40 MG | $1.3M | 2 | 1.8% |
| 13 | FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED FUROSEMIDE INOVAMEDFUROSEMIDE AUROBINDO 40MG TABLETTENFUROSEMIDE AUROBINDO 40MG TABLETTEN (FUR | $1.2M | 4 | 1.8% |
| 14 | QUALIGENS PHARMA PRIVATE LIMITED | $1.2M | 1 | 1.8% |
| 15 | GLAND PHARMA LTD FUROSEMIDE INJ USP 10MG/ML4MLGV AIN00221FUROSEMIDE INJ USP 10MG/ML2MLGV AIN00218FUROSEMIDE INJECTION USP10MG/ML 10ML GVAIN00214 | $995.3K | 4 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Furosemide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals Limited | Warning Letter, August 20 | Yes, 2006 | Yes | Not verified | Received FDA warning letter in August 2019 for data manipulation violations at H |
| Lincoln Pharmaceuticals Ltd | Not Listed | Yes, 1984 | Yes, May 2020 | Not verified | Received EU GMP certification for Khatraj facility in May 2020. |
| Maiva Pharma Private Limited | Approved | Unknown | Unknown | Multiple | Received FDA approval for multiple products, including Furosemide, as of Februar |
| Aurobindo Pharma Ltd | Approved | Unknown | Unknown | Not verified | Manufactures generic pharmaceuticals and APIs; markets products in over 125 coun |
| Alembic Pharmaceuticals Ltd | Approved | Unknown | Unknown | 223 | Received multiple FDA approvals between 2024 and 2025, increasing cumulative AND |
| Intas Pharmaceuticals Ltd | Approved | Yes, 2007 | Yes | Not verified | Received EU GMP certification in April 2007; operates 22 manufacturing plants gl |
| Glenmark Pharmaceuticals Ltd | Approved | Unknown | Unknown | Not verified | Headquartered in Mumbai; operates globally in pharmaceuticals and vaccines. |
| Avet Lifesciences Private Limited | Approved | Unknown | Unknown | Multiple | Received FDA approval for multiple products, including Furosemide, as of Februar |
TransData Nexus reviewed the regulatory standing of 8 leading Furosemide exporters from India. 6 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Furosemide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts numerous pharmaceutical companies specializing in active pharmaceutical ingredients (APIs) and bulk drugs. For instance, A.R. Life Sciences, established in 2007, manufactures a wide range of APIs and intermediates, adhering to Good Manufacturing Practices (GMP) and holding ISO 9001:2015 certification. Additionally, Hy-Gro Chemicals focuses on developing and manufacturing cost-effective APIs and intermediates, emphasizing quality and sustainability.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations and biogenerics manufacturing. Vadodara, in particular, is a significant hub for pharmaceutical industries, hosting numerous companies involved in formulations and biogenerics. For example, Ester Formulations, established in 2000, manufactures and exports a comprehensive range of pharmaceutical formulations, including tablets, capsules, oral liquids, suspensions, soft gelatin capsules, and injectables. Additionally, Schwitz Biotech in Ahmedabad formulates, manufactures, and exports a wide range of pharmaceutical formulations, adhering to FDA, WHO, GMP, and ISO 9002 quality standards.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a crucial export gateway for pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to various international markets. The region hosts several pharmaceutical companies with manufacturing facilities in both Mumbai and Hyderabad, such as Formel Labs, which specializes in producing high-quality active pharmaceutical ingredients. This strategic location enables efficient distribution and export of pharmaceutical products, including Furosemide, to global destinations.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh is known for its tax incentives, attracting numerous pharmaceutical companies to set up manufacturing units. This area offers benefits such as excise duty exemptions and income tax holidays, making it a favorable location for pharmaceutical production. Companies like Theon Pharma, based in Baddi, provide contract manufacturing services across Gujarat and other major cities in India, producing a wide range of pharmaceutical products, including tablets, capsules, syrups, powders, herbal products, and advanced therapeutic formulations.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with over-reliance on a few suppliers, consider engaging with multiple manufacturers across different regions, such as Hyderabad for bulk drugs and Ahmedabad-Vadodara for formulations.
- Evaluate Supplier Certifications: Ensure that potential suppliers hold relevant certifications, such as GMP, ISO 9001:2015, and FDA approvals, to guarantee product quality and compliance with international standards.
- Assess Export Capabilities: Given the significant export volumes to countries like the United States and Canada, prioritize suppliers with established export experience and the necessary regulatory approvals for these markets.
- Consider Logistics and Infrastructure: Leverage regions with robust logistics and export infrastructure, such as the Mumbai-Thane-Raigad area, to facilitate efficient shipping and distribution of Furosemide to international destinations.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Furosemide exporters from India
Baxter Pharmaceuticals India Private Limited — Baxter divests BioPharma Solutions to Advent and Warburg Pincus
Baxter International Inc. announced a definitive agreement to divest its BioPharma Solutions business to Advent International and Warburg Pincus for $4.25 billion. The transaction is expected to close in the second half of 2023, subject to regulatory approvals. - IMPACT: This divestiture may lead to a strategic realignment of Baxter's operations, potentially affecting its Furosemide export capabilities.
Impact: This divestiture may lead to a strategic realignment of Baxter's operations, potentially affecting its Furosemide export capabilities.
Common Questions — Furosemide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which furosemide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED leads with 142 recorded shipments worth $17.8M. GRAVITI PHARMACEUTICALS PRIVATE LIMITED (1,728 shipments) and IPCA LABORATORIES LIMITED (72 shipments) are also established high-volume exporters.
Q How many furosemide manufacturers are there in India?
India has 333 active furosemide exporters with a combined export market of $70.5M across 4,657 shipments to 150 countries. The top 5 suppliers hold 58.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for furosemide from India?
Average FOB unit price: $1.74 per unit, ranging from $0.00 to $1018.62. Average shipment value: $15.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 333 verified Indian exporters of Furosemide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 4,657 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 150 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4,657 Verified Shipments
333 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists